Skip to main content

US ClosedU.S. Closed

Healthcare · Biotechnology

Cullinan Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States.

52W Range

91stpctl

Volume

0.68×avg

Market Cap

1.33BUSD

P/E Ratio

-6.4TTM

Div Yield

-ann

Loading chart data...

Current StateState loading

Cullinan Therapeutics, Inc.

CGEMNASDAQ Global Select·USD·Closed

Cullinan Therapeutics, Inc.

CGEMNASDAQ·USD·Closed

$21.70

−3.98%

$21.70

−$0.90 (3.98%)

52W Range

91stpctl

Volume

0.68×avg

Mkt Cap

1.33BUSD

P/E

-6.4TTM

Div Yield

–ann

CGEM: Cullinan Therapeutics, Inc. Stock Analysis | finqOS